Onyema Greg Chido-Amajuoyi1,2, Rajesh Talluri3,2, Chizoba Wonodi4, Sanjay Shete5,6,7. 1. Departments of Epidemiology and. 2. Contributed equally as co-first authors. 3. Department of Data Science, University of Mississippi Medical Center, Jackson, Mississippi; and. 4. Department of International Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland. 5. Departments of Epidemiology and sshete@mdanderson.org. 6. Biostatistics and. 7. Division of Cancer Prevention and Population Sciences, The University of Texas and Maryland Anderson Cancer Center, Houston, Texas.
Abstract
BACKGROUND AND OBJECTIVES: Routine human papillomavirus (HPV) vaccination is recommended at ages 11 to 12 years and may be initiated as early as 9 years of age. METHODS: Data were derived from the National Immunization Survey-Teen, spanning 2008-2018. Using health care provider-verified vaccination histories, we examined trends in human papillomavirus vaccination up-to-date (HPV-UTD) rates within ages 9 to 12 years. Furthermore, we assessed vaccination status by sociodemographic factors and US state of residence. RESULTS: Overall, amid evidence of recent stagnation, HPV vaccination between ages 9 to 12 increased over the years. Initiation rates rose from 17.3% in 2008 to 62.8% in 2018, and HPV-UTD rates rose from 13.5% in 2011 to 32.8% in 2018. After the inception of gender-neutral HPV vaccination, HPV-UTD rates between 2011 and 2018 rose by 31.9% among boys and only 6.6% among girls. For most of the study period, non-Hispanic Black and Hispanic individuals had higher rates of initiation and HPV-UTD than non-Hispanic white individuals. In 2018, vaccination initiation rates exceeded 70% in several states; however, HPV-UTD rates in most US states were <50%, excluding Rhode Island (61.6%), Colorado (58.7%), Hawaii (53.5%), District of Columbia (53.2%), and Ohio (50%). CONCLUSIONS: HPV vaccination within ages 9 to 12 years is suboptimal. To leverage the substantial benefits of HPV vaccination within this age range, it is imperative that conscious efforts are taken at the national and state levels to promote HPV vaccination for this age group.
BACKGROUND AND OBJECTIVES: Routine human papillomavirus (HPV) vaccination is recommended at ages 11 to 12 years and may be initiated as early as 9 years of age. METHODS: Data were derived from the National Immunization Survey-Teen, spanning 2008-2018. Using health care provider-verified vaccination histories, we examined trends in human papillomavirus vaccination up-to-date (HPV-UTD) rates within ages 9 to 12 years. Furthermore, we assessed vaccination status by sociodemographic factors and US state of residence. RESULTS: Overall, amid evidence of recent stagnation, HPV vaccination between ages 9 to 12 increased over the years. Initiation rates rose from 17.3% in 2008 to 62.8% in 2018, and HPV-UTD rates rose from 13.5% in 2011 to 32.8% in 2018. After the inception of gender-neutral HPV vaccination, HPV-UTD rates between 2011 and 2018 rose by 31.9% among boys and only 6.6% among girls. For most of the study period, non-Hispanic Black and Hispanic individuals had higher rates of initiation and HPV-UTD than non-Hispanic white individuals. In 2018, vaccination initiation rates exceeded 70% in several states; however, HPV-UTD rates in most US states were <50%, excluding Rhode Island (61.6%), Colorado (58.7%), Hawaii (53.5%), District of Columbia (53.2%), and Ohio (50%). CONCLUSIONS: HPV vaccination within ages 9 to 12 years is suboptimal. To leverage the substantial benefits of HPV vaccination within this age range, it is imperative that conscious efforts are taken at the national and state levels to promote HPV vaccination for this age group.
Authors: Mahboobeh Safaeian; Joshua N Sampson; Yuanji Pan; Carolina Porras; Troy J Kemp; Rolando Herrero; Wim Quint; Leen Jan van Doorn; John Schussler; Douglas R Lowy; John Schiller; Mark T Schiffman; Ana Cecilia Rodriguez; Mitchell H Gail; Allan Hildesheim; Paula Gonzalez; Ligia A Pinto; Aimée R Kreimer Journal: J Natl Cancer Inst Date: 2018-02-01 Impact factor: 13.506
Authors: Ahmedin Jemal; Edgar P Simard; Christina Dorell; Anne-Michelle Noone; Lauri E Markowitz; Betsy Kohler; Christie Eheman; Mona Saraiya; Priti Bandi; Debbie Saslow; Kathleen A Cronin; Meg Watson; Mark Schiffman; S Jane Henley; Maria J Schymura; Robert N Anderson; David Yankey; Brenda K Edwards Journal: J Natl Cancer Inst Date: 2013-01-07 Impact factor: 13.506
Authors: Kimberley Kavanagh; Kevin G Pollock; Kate Cuschieri; Tim Palmer; Ross L Cameron; Cameron Watt; Ramya Bhatia; Catherine Moore; Heather Cubie; Margaret Cruickshank; Chris Robertson Journal: Lancet Infect Dis Date: 2017-09-28 Impact factor: 25.071
Authors: Haluk Damgacioglu; Kalyani Sonawane; Jagpreet Chhatwal; David R Lairson; Gary M Clifford; Anna R Giuliano; Ashish A Deshmukh Journal: Lancet Reg Health Am Date: 2021-12-15
Authors: Puja Aggarwal; Katherine A Hutcheson; Adam S Garden; Frank E Mott; Charles Lu; Ryan P Goepfert; Clifton D Fuller; Stephen Y Lai; G Brandon Gunn; Mark S Chambers; Erich M Sturgis; Ehab Y Hanna; Sanjay Shete Journal: Cancer Date: 2021-08-06 Impact factor: 6.860